

Cameron J Turtle

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4656410/cameron-j-turtle-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

7,696
citations

34
h-index

75
g-index

75
ext. papers

10,228
ext. citations

5.9
avg, IF

6.14
L-index

#	Paper	IF	Citations
69	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. <i>Blood Advances</i> , 2021 ,	7.8	5
68	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. <i>Blood</i> , 2021 , 138, 3872-3872	2.2	1
67	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aB NHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , 2021 138, 422-428	2.2	2
66	Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy. <i>Blood</i> , 2021 , 138, 2776-2776	2.2	
65	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study 2021 , 9,		1
64	Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 98-106	2.2	0
63	Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. <i>JCI Insight</i> , 2021 , 6,	9.9	3
62	CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. <i>BioDrugs</i> , 2021 , 35, 281-302	7.9	7
61	Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry. <i>Journal of Immunological Methods</i> , 2021 , 492, 112955	2.5	0
60	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy 2021 ,		3
59	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021 , 137, 323-335	2.2	39
58	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. <i>Journal of Medical Virology</i> , 2021 , 93, 2270-2280	19.7	20
57	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , 2021 , 17, 3549-3560	3.6	2
56	Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. <i>Blood</i> , 2021 ,	2.2	9
55	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020 , 135, 1650-1660	2.2	115
54	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1706-1715	4.4	34
53	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. <i>Blood</i> , 2020 , 136, 137-139	2.2	29

52	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 653-664	5.4	18
51	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , 2020 , 58, 58-64	4	19
50	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. <i>Blood</i> , 2020 , 136, 1-2	2.2	1
49	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 38-39	2.2	2
48	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events 2020 , 8,		66
47	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. <i>Blood</i> , 2020 , 136, 37-38	2.2	4
46	Cytokines in CAR T Cell-Associated Neurotoxicity. <i>Frontiers in Immunology</i> , 2020 , 11, 577027	8.4	37
45	Neurotoxicities After CAR T-Cell Immunotherapy 2020 , 83-105		5
44	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020 , 4, 4869-4872	7.8	8
43	Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 1233-1244	35.1	395
42	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020 , 4, 3239-3245	7.8	6
41	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 34-43	4.7	40
40	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 26-33	4.7	100
39	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019 , 94, E209-E213	7.1	39
38	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , 2019 , 133, 1652-1663	2.2	158
37	Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. <i>Bone Marrow Transplantation</i> , 2019 , 54, 780-784	4.4	29
36	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , 2019 , 134, 636-640	2.2	89
35	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Blood</i> , 2019 , 134, 4453-4453	2.2	1

34	Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model. <i>Blood</i> , 2019 , 134, 2866-2866	2.2	4
33	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019 , 133, 1876-1887	2.2	126
32	Toxicities of CD19 CAR-T cell immunotherapy. <i>American Journal of Hematology</i> , 2019 , 94, S42-S49	7.1	57
31	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019 , 3, 3062-3069	7.8	37
30	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , 2019 , 3, 3590-3601	7.8	27
29	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 625-638	4.7	874
28	Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. <i>Journal of Immunology</i> , 2019 , 202, 476-483	5.3	27
27	Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. <i>Current Research in Translational Medicine</i> , 2018 , 66, 50-52	3.7	67
26	Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. <i>Cancer Discovery</i> , 2018 , 8, 750-763	24.4	136
25	Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 242-251	4.7	46
24	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood</i> , 2018 , 131, 121-130	2.2	225
23	Toxicities of CD19-targeted CAR-T cell therapy. <i>Pathology</i> , 2018 , 50, S39-S40	1.6	
22	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , 2018 , 132, 94-94	2.2	10
21	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1011-1011	2.2	62
20	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. <i>CNS Drugs</i> , 2018 , 32, 1091-1101	6.7	110
19	Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. <i>Drugs</i> , 2017 , 77, 237-245	12.1	84
18	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. <i>Cancer Discovery</i> , 2017 , 7, 1404-1419	24.4	649
17	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3010-3020	2.2	396

16	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. <i>Blood</i> , 2017 , 130, 2295-2306	2.2	522
15	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. <i>Science Translational Medicine</i> , 2016 , 8, 355ra116	17.5	613
14	CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. <i>Oncot Immunology</i> , 2016 , 5, e1168555	7.2	14
13	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 56-56	2.2	10
12	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2123-38	15.9	1143
11	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> , 2016 , 127, 2406-10	2.2	436
10	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , 2015 , 126, 184-184	2.2	36
9	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 3773-3773	2.2	29
8	Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 705-16	4.7	75
7	Engineered T cells for anti-cancer therapy. <i>Current Opinion in Immunology</i> , 2012 , 24, 633-9	7.8	62
6	Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2011 , 23, 299-305	7.8	31
5	Generation and Signaling Function of CD19 Chimeric Antigen Receptor Modified CD8+ T Cells Derived From Virus-Specific Central Memory Cells for Adoptive Therapy After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2011 , 118, 2978-2978	2.2	
4	Overlap and effective size of the human CD8+ T cell receptor repertoire. <i>Science Translational Medicine</i> , 2010 , 2, 47ra64	17.5	286
3	Artificial antigen-presenting cells for use in adoptive immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2010 , 16, 374-81	2.2	66
2	A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. <i>Immunity</i> , 2009 , 31, 834-44	32.3	140
1	Generation of CD8+ Cytotoxic T Cell Clones Recognizing BMI1-Derived Peptides. <i>Blood</i> , 2008 , 112, 2909-2909	2	